Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Decoy Therapeutics Inc.FLKS · Entity 937 | Chief Medical Officer | January 17, 2018 | January 19, 2018 |
| RELMADA THERAPEUTICS, INC.RLMD · Entity 5498 | EVP, Head of R&D | March 09, 2020 | March 16, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Decoy Therapeutics Inc.
Report date January 17, 2018 · Filed January 19, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.98 · Expires 2028-01-17 | Direct | 100,000 |
Reported balance
After 2018-01-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-01-17 · Grant · Acquired 100,000 · Balance 100,000 F1: The stock option will vest in 48 successive equal monthly installments measured from January 17, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option will vest in 48 successive equal monthly installments measured from January 17, 2018.
RELMADA THERAPEUTICS, INC.
Report date March 09, 2020 · Filed March 16, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Options to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $45.61 · Expires 2030-03-09 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-03-09 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: Options granted on March 9, 2020 to purchase an aggregate of 350,000 shares of common stock. A total of 25% of the options will vest one year from the grant date, and the remaining 75% shall vest in equal quarterly increments of 6.25% of the initial option grant over the following three year period. |
Filing footnotes · ownership attribution and instrument terms
F1: Options granted on March 9, 2020 to purchase an aggregate of 350,000 shares of common stock. A total of 25% of the options will vest one year from the grant date, and the remaining 75% shall vest in equal quarterly increments of 6.25% of the initial option grant over the following three year period.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 17, 2018 Filed Jan 19, 2018 09:43 UTC | Decoy Therapeutics Inc. FLKS · Entity 937 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $3.98 | $0.00 |
DisclosureSEC source: 0001615219-18-000004 · wf-form4_151637301079957.xml · derivative · entry 1 Wessel Thomas · CIK 0001456055 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2028-01-17 F1 · derivative.exercise_date: The stock option will vest in 48 successive equal monthly installments measured from January 17, 2018. Read SEC document |
| January 18, 2017 Filed Jan 20, 2017 09:03 UTC | Decoy Therapeutics Inc. FLKS · Entity 937 | GrantStock Option (right to buy) · Derivative | 85,000 | $0.00 Strike: $4.58 | $0.00 |
DisclosureSEC source: 0001615219-17-000010 · wf-form4_148492101344004.xml · derivative · entry 1 Wessel Thomas · CIK 0001456055 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2027-01-18 F1 · derivative.exercise_date: The stock option will vest in 48 successive equal monthly installments measured from January 18, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.